Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Allakos Inc (ALLK)

Allakos Inc (ALLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,222
  • Shares Outstanding, K 88,544
  • Annual Sales, $ 0 K
  • Annual Income, $ -185,700 K
  • 60-Month Beta 0.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.63
Trade ALLK with:

Options Overview Details

View History
  • Implied Volatility 102.51% ( +20.11%)
  • Historical Volatility 64.85%
  • IV Percentile 51%
  • IV Rank 15.97%
  • IV High 605.67% on 12/04/23
  • IV Low 6.90% on 02/29/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 50
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 2,474
  • Open Int (30-Day) 2,068

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.45
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +16.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9799 +22.46%
on 04/25/24
1.3000 -7.69%
on 05/09/24
+0.0400 (+3.45%)
since 04/10/24
3-Month
0.9799 +22.46%
on 04/25/24
1.6900 -28.99%
on 03/01/24
-0.1400 (-10.45%)
since 02/09/24
52-Week
0.9799 +22.46%
on 04/25/24
5.6400 -78.72%
on 08/07/23
-3.0900 (-72.03%)
since 05/10/23

Most Recent Stories

More News
Why Shares of Allakos Are Up Wednesday

The stock is bouncing back from a recent 52-week low.

ALLK : 1.2000 (-6.98%)
Why Allakos Stock Skyrocketed Nearly 9% Higher Today

The company is poised to report a critical set of clinical data in the coming months.

ALLK : 1.2000 (-6.98%)
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

NVAX : 8.88 (+98.66%)
ADMA : 8.81 (+27.13%)
ALLK : 1.2000 (-6.98%)
AKRO : 19.65 (-5.53%)
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.

ADMA : 8.81 (+27.13%)
BLPH : 0.0562 (unch)
ALLK : 1.2000 (-6.98%)
AKRO : 19.65 (-5.53%)
Why Allakos Stock Was Heating Up Today

A notable analyst upgrade had investors piling into this clinical-stage biotech stock today.

PIPR : 212.46 (-0.26%)
ALLK : 1.2000 (-6.98%)
Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade

Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALLK : 1.2000 (-6.98%)
Why Allakos Stock Is on Fire Today

Investors appear to be getting into position ahead of a major upcoming catalyst.

ALLK : 1.2000 (-6.98%)
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...

ALLK : 1.2000 (-6.98%)
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...

ALLK : 1.2000 (-6.98%)
INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK

The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK...

ALLK : 1.2000 (-6.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 1.3067
2nd Resistance Point 1.2733
1st Resistance Point 1.2367
Last Price 1.2000
1st Support Level 1.1667
2nd Support Level 1.1333
3rd Support Level 1.0967

See More

52-Week High 5.6400
Fibonacci 61.8% 3.8598
Fibonacci 50% 3.3099
Fibonacci 38.2% 2.7601
Last Price 1.2000
52-Week Low 0.9799

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar